ReferenceMetabolic & incretin research
Cagrilintide
AM833 · long-acting amylin analog
Long-acting amylin-receptor agonist studied alongside incretin peptides in metabolic research.
About Cagrilintide
Cagrilintide is a long-acting amylin analog investigated in metabolic research, frequently studied in combination with GLP-1 agonists such as semaglutide. It is used as a reference amylin-pathway agonist in laboratory model systems. TagPep is adding cagrilintide as a research-use-only reference material.
Mechanism studied in research
Agonism at amylin and calcitonin receptors — a satiety-signaling axis studied in parallel with, and complementary to, the incretin pathway.
Areas of research investigation
- Amylin-receptor signaling assays
- Amylin + GLP-1 combination research
- Satiety-pathway model systems
- Comparative agonist studies
Laboratory handling
Supplied lyophilized; reconstituted with bacteriostatic or sterile water for research and stored refrigerated, with the powder held frozen and light-protected.
Comparisons
Cagrilintide research FAQ
What is cagrilintide studied with?
In research it is frequently paired with GLP-1 agonists such as semaglutide to study complementary amylin-and-incretin signaling. TagPep supplies it as research-use-only reference material.
Is cagrilintide an incretin?
No — it is an amylin analog. It acts on amylin/calcitonin receptors rather than the GLP-1/GIP incretin receptors, which is why it is studied as a complementary pathway.
Research use only. Cagrilintide is supplied as a laboratory reference material for in-vitro and research applications. It is not a drug, supplement or medical product, and is not intended for human or veterinary use, consumption, or clinical application.